INS and cystic fibrosis-related diabetes: Most of the interest in CFTR modulator therapy in CFRD has focused on potential benefit, including whether it might prevent or delay onset of diabetes if started early enough in life, improve insulin secretion, and/or reduce CFRD-associated mortality.